ES2423005T3 - Activación por glucolípidos bacterianos de linfocitos NKT restringidos por CD1d - Google Patents

Activación por glucolípidos bacterianos de linfocitos NKT restringidos por CD1d Download PDF

Info

Publication number
ES2423005T3
ES2423005T3 ES06733921T ES06733921T ES2423005T3 ES 2423005 T3 ES2423005 T3 ES 2423005T3 ES 06733921 T ES06733921 T ES 06733921T ES 06733921 T ES06733921 T ES 06733921T ES 2423005 T3 ES2423005 T3 ES 2423005T3
Authority
ES
Spain
Prior art keywords
glycolipid
alkyl
nkt
lymphocytes
pbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06733921T
Other languages
English (en)
Spanish (es)
Inventor
Luc Teyton
Albert Bendelac
Paul Savage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Brigham Young University
Scripps Research Institute
Original Assignee
University of Chicago
Brigham Young University
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago, Brigham Young University, Scripps Research Institute filed Critical University of Chicago
Application granted granted Critical
Publication of ES2423005T3 publication Critical patent/ES2423005T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06733921T 2005-01-28 2006-01-26 Activación por glucolípidos bacterianos de linfocitos NKT restringidos por CD1d Expired - Lifetime ES2423005T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64815305P 2005-01-28 2005-01-28
US648153P 2005-01-28
PCT/US2006/002781 WO2006083671A2 (en) 2005-01-28 2006-01-26 Bacterial glycolipid activation of cd1d-restricted nkt cells

Publications (1)

Publication Number Publication Date
ES2423005T3 true ES2423005T3 (es) 2013-09-17

Family

ID=36777772

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06733921T Expired - Lifetime ES2423005T3 (es) 2005-01-28 2006-01-26 Activación por glucolípidos bacterianos de linfocitos NKT restringidos por CD1d

Country Status (12)

Country Link
US (1) US9295722B2 (https=)
EP (1) EP1848813B1 (https=)
JP (1) JP5053101B2 (https=)
AU (1) AU2006211485B2 (https=)
BR (1) BRPI0607299A2 (https=)
CA (1) CA2593715C (https=)
DK (1) DK1848813T3 (https=)
ES (1) ES2423005T3 (https=)
PL (1) PL1848813T3 (https=)
PT (1) PT1848813E (https=)
WO (1) WO2006083671A2 (https=)
ZA (1) ZA200706208B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
PL2056842T3 (pl) 2006-04-07 2013-03-29 Scripps Research Inst Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use
JP2010523724A (ja) * 2007-04-13 2010-07-15 アカデミア シニカ α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用
US8916164B2 (en) 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
AU2013202865B2 (en) * 2007-11-07 2015-03-19 Abivax Increase of immune response and targeting by antigens and/or drug linkage
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
US8207135B2 (en) 2007-12-05 2012-06-26 Wittycell Compositions for and methods of enhancing the immune response to antigens
JP5809560B2 (ja) 2008-10-08 2015-11-11 アビヴァックス インフルエンザに対して使用するためのワクチン組成物
WO2010097700A1 (en) 2009-02-25 2010-09-02 Supratek Pharma, Inc. Bendamustine cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CA2893918C (en) * 2012-12-06 2020-11-24 Callaghan Innovation Research Limited Conjugate compounds
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN115666586A (zh) * 2020-04-23 2023-01-31 加州大学评议会 通过激活iNKT细胞清除衰老细胞
FR3117776B1 (fr) * 2020-12-18 2024-03-08 Oreal Extrait de bactérie du genreSphingomonas
EP4262997A1 (en) * 2020-12-18 2023-10-25 L'oreal Extract of bacteria of the genus sphingomonas
CN117222414A (zh) 2021-03-01 2023-12-12 脱落性治疗公司 用于激活恒定自然杀伤t-细胞的化合物和用于消除炎性衰老细胞的方法
WO2024107463A1 (en) * 2022-11-14 2024-05-23 The Trustees Of Columbia University In The City Of New York 7dw8-5 treatment for covid-19 and other virus-induced respiratory infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (https=) 1992-07-16 1995-11-01 Kirin Brewery
EP0666268B1 (en) 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
EP0694558B1 (en) 1993-04-15 1999-01-27 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
RO117533B1 (ro) 1993-05-14 2002-04-30 Cytel Corp San Diego DERIVATI DE ANALOGI SIALIL LeX INHIBITORI AI ADEZIUNII CELULARE SI COMPOZITIE FARMACEUTICA CU ACESTIA
ATE286735T1 (de) 1997-04-10 2005-01-15 Kirin Brewery Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten
JP2001515868A (ja) * 1997-09-12 2001-09-25 ブライハム アンド ウイメンズ ホスピタル Ｃｄ１制限免疫応答のための合成抗原
AU2001252599A1 (en) 2000-04-28 2001-11-12 Orient Cancer Therapy Co., Ltd. Remedies for cancer
AU2002213588A1 (en) * 2000-06-05 2001-12-17 The Brigham And Women's Hospital, Inc. Soluble cd1 compositions and uses thereof
DK2336187T3 (en) * 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
KR100549866B1 (ko) * 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
CN1578667A (zh) 2001-11-06 2005-02-09 东方癌症治疗株式会社 抗癌组合物
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
WO2004094444A1 (en) 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
JP5005541B2 (ja) 2004-09-03 2012-08-22 ザ ユニヴァーシティー オヴ シカゴ Ｎｋｔ細胞の活性化方法
PL2056842T3 (pl) 2006-04-07 2013-03-29 Scripps Research Inst Modyfikowany galaktozyloceramid do leczenia chorób nowotworowych
AU2007269299B2 (en) 2006-06-30 2013-01-17 Brigham Young University Adjuvants and methods of use

Also Published As

Publication number Publication date
EP1848813A4 (en) 2008-07-09
US9295722B2 (en) 2016-03-29
AU2006211485B2 (en) 2011-04-14
PT1848813E (pt) 2013-07-15
DK1848813T3 (da) 2013-07-15
US20080279894A1 (en) 2008-11-13
EP1848813B1 (en) 2013-04-10
CA2593715C (en) 2015-05-05
WO2006083671A2 (en) 2006-08-10
AU2006211485A1 (en) 2006-08-10
WO2006083671B1 (en) 2007-04-12
CA2593715A1 (en) 2006-08-10
PL1848813T3 (pl) 2013-09-30
EP1848813A2 (en) 2007-10-31
BRPI0607299A2 (pt) 2009-08-25
ZA200706208B (en) 2008-04-30
JP5053101B2 (ja) 2012-10-17
JP2008528608A (ja) 2008-07-31
WO2006083671A3 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
ES2423005T3 (es) Activación por glucolípidos bacterianos de linfocitos NKT restringidos por CD1d
Aggarwal et al. Diverse macrophage populations mediate acute lung inflammation and resolution
Prioult et al. Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation?
Chow et al. NLRP3 suppresses NK cell–mediated responses to carcinogen-induced tumors and metastases
Xu et al. Direct and indirect role of Toll-like receptors in T cell mediated immunity
Klezovich-Benard et al. Mechanisms of NK cell-macrophage Bacillus anthracis crosstalk: a balance between stimulation by spores and differential disruption by toxins
Duramad et al. Pharmacologic expansion of donor-derived, naturally occurring CD4+ Foxp3+ regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models
Arora et al. CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis
Brutkiewicz et al. CD1d-mediated antigen presentation to natural killer T (NKT) cells
Haque et al. Neem (Azadirachta indica) leaf preparation induces prophylactic growth inhibition of murine Ehrlich carcinoma in Swiss and C57BL/6 mice by activation of NK cells and NK-T cells
Chang et al. Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine
Davies et al. Mechanisms of BCG action: I. The induction of nonspecific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses
de Campos et al. Adjuvant Pam3CSk4 does not improve the immunization against Cryptococcus gattii infection in C57BL/6 mice
Mittal Cyclic GMP-AMP synthase regulates the development of experimental autoimmune encephalomyelitis
McPherson Evaluation of the Mode of Action of Sulfated Lactosyl Archaeol Adjuvant: Interaction with L-selectin and Impact of Administration Route
US20080152626A1 (en) Method for Activating Cd8 T Cells
Elsner et al. Salmonella Infection Blocks GC Development Via IL-12 Dependent Inhibition of T FH Differentiation
Danielli CALHM6: Function in the innate immune system and role in infectious diseases
Aldridge Jr Immunobiology of mice infected with larval Taenia crassiceps
Müller Charakterisierung der Rolle von XIAP in der Modulation des entzündlichen Zelltodes und dessen Konsequenzen
Preciado-Llanes Inhibition of T-cell responses by microbes and immune cells
Nembrini et al. 4.3 Inhalation of bacteria suppresses ensuing Th2 effector responses by long-term modulation of lung dendritic cell function.
Müller Characterization of the role of XIAP in modulating inflammatory death and its consequences
Marguti Immune Response and Tissue Cytoprotection Two Sides of the Same Coin in Immunopathology
McCurdy The role of Toll-like receptors in Mast cell activation.